ProMIS Neurosciences Inc.
Business
ProMIS Neurosciences is a clinical-stage biopharmaceutical company developing a pipeline of monoclonal antibodies and therapeutic vaccines targeting misfolded toxic proteins implicated in neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple system atrophy, and schizophrenia. The company's lead program, PMN310, is a humanized antibody selectively targeting toxic amyloid-beta oligomers and is currently in Phase 1b clinical trials for Alzheimer's disease. The company utilizes its proprietary EpiSelect computational platform to identify disease-specific epitopes on misfolded proteins and generate antibody therapeutics and vaccine candidates. Geographic focus includes the United States and Canada, with commercialization through strategic partnerships.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 33 | 11 | 8 | 16 | 5 | |
| General and administrative | 7 | 6 | 6 | 7 | 4 | |
| Total operating expenses | 40 | 17 | 14 | 23 | 8 | |
| Loss from operations | −40 | −17 | −14 | −23 | −8 | |
| Change in fair value of financial instruments | 5,592 | 23 | 866,738 | 4 | −1 | |
| Interest expense | — | −76,775 | −201,390 | — | — | |
| Other income | 442,569 | 626,184 | 384,903 | 115,525 | 12,909 | |
| Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE | — | −4 | — | — | — | |
| Total other income, net | 448,161 | 20 | 1 | 5 | −1 | |
| Net (loss) income | −40 | 3 | −13 | −18 | −10 | |
| Net (loss) income per share, basic | −22.61 | 2.68 | −1.07 | −2.41 | −1.69 | |
| Net (loss) income per share, diluted | −22.61 | 2.63 | −1.07 | −2.41 | −1.69 | |
| Weighted-average outstanding Common Shares, basic | 2 | 1 | 12 | 8 | 6 | |
| Weighted-average outstanding Common Shares, diluted | 2 | 1 | 12 | 8 | 6 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 6 | 13 | 13 | 6 | 17 | |
| Short-term investments | 33,753 | 33,051 | 32,358 | 31,009 | 33,248 | |
| Prepaid expenses and other current assets | 3 | 6 | 988,641 | 996,682 | 737,316 | |
| Total current assets | 9 | 19 | 14 | 7 | 18 | |
| Total assets | 9 | 19 | 14 | 7 | 18 | |
| Accounts payable | 3 | 2 | 8 | 3 | 408,981 | |
| Accrued liabilities | 8 | 480,962 | 2 | 3 | 520,093 | |
| Total current liabilities | 10 | 2 | 9 | 6 | 929,074 | |
| Share-based compensation liability | 29,182 | 199,263 | 422,002 | — | — | |
| Warrant liability | — | 5,592 | 94,185 | 2 | 2 | |
| Total liabilities | 10 | 2 | 10 | 8 | 12 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common Shares, no par value, unlimited shares authorized, 2,152,397 and 1,307,520 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — | — | — | — | |
| Additional paid-in capital | 130 | 108 | 98 | 79 | 68 | |
| Accumulated other comprehensive loss | −371,184 | −371,184 | −371,184 | −195,369 | −187,919 | |
| Accumulated deficit | −130 | −91 | −93 | −80 | −62 | |
| Total shareholders' (deficit) equity | −1 | 16 | 4 | −1 | 6 | |
| Total liabilities and shareholders' (deficit) equity | 9 | 19 | 14 | 7 | 18 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net (loss) income | −40 | 3 | −13 | −18 | −10 | |
| Share-based compensation expense | 857,628 | 825,808 | 271,542 | 487,630 | 515,629 | |
| Change in fair value of financial instruments | −5,592 | −23 | −866,738 | −3 | 2 | |
| Prepaid expenses and other current assets | 3 | −5 | −187,321 | −318,747 | −600,635 | |
| Accounts payable | 805,952 | −6 | 5 | 3 | −31,654 | |
| Accrued liabilities | 7 | −1 | −2 | 3 | 471,463 | |
| Net cash used in operating activities | −28 | −27 | −11 | −17 | −9 | |
| Purchase of short-term investments | −33,753 | −33,051 | −32,358 | −31,009 | −33,102 | |
| Maturity of short-term investment | 33,051 | 32,358 | 31,009 | 31,009 | 33,069 | |
| Net cash used in investing activities | −702 | −693 | −1,349 | −1,981 | 94,618 | |
| Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs | 708,468 | 190,274 | — | 5 | 16 | |
| Proceeds from exercise of pre-funded warrants | 3,050 | 28,038 | 3,600 | — | — | |
| Net cash provided by financing activities | 21 | 28 | 18 | 6 | 26 | |
| Net (decrease) increase in cash | −7 | 693,021 | 7 | −11 | 16 | |
| Reclassification of July 2024 PIPE warrants from liability to equity | — | 9 | — | — | — | |
| Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital | −170,081 | 222,739 | 681,308 | — | — | |
| Cash paid for interest | — | 76,775 | 201,390 | 87,069 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ProMIS Neurosciences Inc.'s CIK number?
ProMIS Neurosciences Inc.'s SEC CIK number is 0001374339 (1374339). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ProMIS Neurosciences Inc.'s SEC filings?
All of ProMIS Neurosciences Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ProMIS Neurosciences Inc. last report earnings?
ProMIS Neurosciences Inc. (PMN) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-058967). This is ProMIS Neurosciences Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ProMIS Neurosciences Inc.'s most recent earnings 8-K?
ProMIS Neurosciences Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001104659-26-058967. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ProMIS Neurosciences Inc.'s latest earnings 8-K →
Look up any company's CIK number →